Effects of phosphate binders on bone biomarkers and bone density in haemodialysis patients.

Suwasin UdomkarnjananunJeerath PhannajitKullaya TakkavatakarnMonravee TumkositKanaungnit KingpetchYingyos AvihingsanonKearkiat PraditpornsilpaSomchai Eiam-OngPaweena Susantitaphong

Published in: Nephrology (Carlton, Vic.) (2022)

Switching from CPB to NCPB might increase bone biomarkers and prevent the development of adynamic bone disease. On the contrary, NCPB should be cautiously used in haemodialysis patients who already had low BMD. P1NP, BALP and TRAP5b could be used to guide the appropriate management, including anti-resorptive and anabolic medications, and predict low BMD in haemodialysis patients treated with phosphate binders.

Keyphrases

end stage renal disease
bone mineral density
chronic kidney disease
peritoneal dialysis
soft tissue
bone loss
ejection fraction
postmenopausal women
newly diagnosed
body composition
patient reported